S*BIO Pte Ltd of Singapore announced its second drug development deal this month. The company will sell a worldwide license to its early-stage cancer drug, a multi-kinase inhibitor, to Tragara Pharmaceuticals of San Diego in a transaction valued at up to $112.5 million. Two weeks ago, S*BIO optioned its JAK2 inhibitor program, including two drug candidates, to Onyx Pharmaceuticals for up to $550 million. More details...

Stock Symbols: (NSDQ: ONXX) (NYSE: NVS)